File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Chemotherapy for advanced (stage IIIB and stage IV) non-small cell lung cancer: The Hong Kong perspective

TitleChemotherapy for advanced (stage IIIB and stage IV) non-small cell lung cancer: The Hong Kong perspective
Authors
Issue Date1998
PublisherBlackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/RES
Citation
Respirology, 1998, v. 3 n. 3, p. 145-149 How to Cite?
AbstractNon-small cell lung cancer (NSCLC) accounts for about 80% of all primary lung cancers, and 60% of cases present as advanced stages IIIB and IV disease. Traditionally, treatment of stages IIIB and IV disease was only symptomatic (including radiotherapy) and supportive care, and cytotoxic chemotherapy was relatively ineffective. Our initial clinical trials, using MACC, FuAM, FAM, Hi-FAM and cisplatin-VP16, gave response rates of 5-20% and a stabilization rate of 7-25%, with no impact on median survival. Our most recent chemotherapy regimen MIP (mitomycin-C, ifosfamide and cisplatin) proved to be more effective with a 44% response rate and a 28% stabilzation rate, and produced a significantly longer median survival (32 weeks) than best supportive care alone (19.5 weeks, P<0.05). The response rate further increased to 62.5% with dose intensification and GM-CSF support. Chemotherapy can now be recommended to motivated, well-informed patients with good performance status in institutions with experience in cancer chemotherapy on a protocol basis. The most recent addition of new effective cytotoxic agents such as paclitaxel, docetaxel, gemitabine and vinorelbine gave promising results in NSCLC, and optimal combinations and dose schedules are being defined by multicentred studies.
Persistent Identifierhttp://hdl.handle.net/10722/162226
ISSN
2015 Impact Factor: 3.078
2015 SCImago Journal Rankings: 1.157
References

 

DC FieldValueLanguage
dc.contributor.authorLam, WKen_US
dc.contributor.authorTsang, KWTen_US
dc.contributor.authorIp, MSMen_US
dc.date.accessioned2012-09-05T05:18:15Z-
dc.date.available2012-09-05T05:18:15Z-
dc.date.issued1998en_US
dc.identifier.citationRespirology, 1998, v. 3 n. 3, p. 145-149en_US
dc.identifier.issn1323-7799en_US
dc.identifier.urihttp://hdl.handle.net/10722/162226-
dc.description.abstractNon-small cell lung cancer (NSCLC) accounts for about 80% of all primary lung cancers, and 60% of cases present as advanced stages IIIB and IV disease. Traditionally, treatment of stages IIIB and IV disease was only symptomatic (including radiotherapy) and supportive care, and cytotoxic chemotherapy was relatively ineffective. Our initial clinical trials, using MACC, FuAM, FAM, Hi-FAM and cisplatin-VP16, gave response rates of 5-20% and a stabilization rate of 7-25%, with no impact on median survival. Our most recent chemotherapy regimen MIP (mitomycin-C, ifosfamide and cisplatin) proved to be more effective with a 44% response rate and a 28% stabilzation rate, and produced a significantly longer median survival (32 weeks) than best supportive care alone (19.5 weeks, P<0.05). The response rate further increased to 62.5% with dose intensification and GM-CSF support. Chemotherapy can now be recommended to motivated, well-informed patients with good performance status in institutions with experience in cancer chemotherapy on a protocol basis. The most recent addition of new effective cytotoxic agents such as paclitaxel, docetaxel, gemitabine and vinorelbine gave promising results in NSCLC, and optimal combinations and dose schedules are being defined by multicentred studies.en_US
dc.languageengen_US
dc.publisherBlackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/RESen_US
dc.relation.ispartofRespirologyen_US
dc.subject.meshAntineoplastic Agents - Therapeutic Useen_US
dc.subject.meshCarcinoma, Non-Small-Cell Lung - Drug Therapy - Mortality - Pathologyen_US
dc.subject.meshHong Kongen_US
dc.subject.meshHumansen_US
dc.subject.meshLung Neoplasms - Drug Therapy - Mortality - Pathologyen_US
dc.subject.meshNeoplasm Stagingen_US
dc.subject.meshSurvival Analysisen_US
dc.titleChemotherapy for advanced (stage IIIB and stage IV) non-small cell lung cancer: The Hong Kong perspectiveen_US
dc.typeArticleen_US
dc.identifier.emailIp, MSM:msmip@hku.hken_US
dc.identifier.authorityIp, MSM=rp00347en_US
dc.description.naturelink_to_OA_fulltexten_US
dc.identifier.doi10.1111/j.1440-1843.1998.tb00113.x-
dc.identifier.pmid9767612-
dc.identifier.scopuseid_2-s2.0-0031768098en_US
dc.identifier.hkuros41312-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0031768098&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume3en_US
dc.identifier.issue3en_US
dc.identifier.spage145en_US
dc.identifier.epage149en_US
dc.publisher.placeAustraliaen_US
dc.identifier.scopusauthoridLam, WK=7203021937en_US
dc.identifier.scopusauthoridTsang, KWT=7201555024en_US
dc.identifier.scopusauthoridIp, MSM=7102423259en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats